Journal of International Psychiatry

[Abstract] Objective: To compare the effects of two doses of olanzapine in the treatment of mental disorders caused by cerebrovascular disease on serum homocysteine (Homocysteine，Hcy), oxidized low-density lipoprotein (Oxidized Low Den-Sity Lipoprotein，ox-LDL) levels and cognitive function. Methods: A total of 122 patients with mental disorders caused by cerebrovascular disease who visited our hospital from December 2019~December 2022 were included in this study, and were divided into two groups, low-dose group and high-dose group, with 61 cases in each group. 5 mg/day in the low-dose group; The high-dose group administered 15 mg/day for 8 weeks. The clinical manifestations, Brief Psychiatric Rating Scale（BRPS） and Positive and Negative Syndrome Scale（PNASS）scores, Hcy and ox-LDL levels before and after treatment were compared between the two groups. Result: The total effective rate was 83.6% (51/61) in the low-dose group and 75.4% (46/61) in the high-dose group. The BRPS and PANSS scores of the two groups after treatment were lower than those before treatment. The levels of Hcy and ox-LDL were significantly reduced in the two groups after treatment, and the levels of Hcy and ox-LDL in the low-dose group after treatment were lower than those in the high-dose group. Conclusion: olanzapine can be used for mental disorders caused by cerebrovascular disease, the two doses have comparable effects, and from the perspective of drug safety, small doses are more recommended.

[Key words]: Mental Disorders Caused by Cerebrovascular Disease; Olanzapine; Medication Safety; Drug Dosage